Similarly, paclitaxel-resistant triple-negative breast cancer cells were more sensitive to ABT263 than their parental counterparts indicating that, at least in some tumour types, also BCL2 and BCL-XL may be highly promising targets. This evidence concerns the gene BCL2 and neoplasm.